Literature DB >> 11594758

Green tea constituent (--)-epigallocatechin-3-gallate inhibits topoisomerase I activity in human colon carcinoma cells.

S J Berger1, S Gupta, C A Belfi, D M Gosky, H Mukhtar.   

Abstract

DNA topoisomerases I and II are essential for cell survival and play critical roles in DNA metabolism and structure. Inhibitors of topoisomerase constitute a novel family of antitumor agents with demonstrated clinical activity in human malignancies. The clinical use of these agents is limited due to severe toxic effects on normal cells. Therefore, there is a need to develop novel, nontoxic topoisomerase inhibitors that have the ability to spare normal cells. Recent studies have shown that green tea and its major polyphenolic constituent, epigallocatechin-3-gallate (EGCG), impart growth inhibitory responses to cancer cells but not to normal cells. Based on the knowledge that EGCG induces DNA damage, cell cycle arrest, and apoptosis, we considered the possibility of the involvement of topoisomerase in the antiproliferative response of EGCG. Here, for the first time, we show that EGCG inhibits topoisomerase I, but not topoisomerase II in several human colon carcinoma cell lines. Based on this study it is tempting to suggest that combination of EGCG with other conventional topoisomerase inhibitors could be an improved strategy for treatment of colon cancer. The possible role of EGCG as a chemotherapeutic agent needs to be investigated. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11594758     DOI: 10.1006/bbrc.2001.5736

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

Review 1.  Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications.

Authors:  Brahma N Singh; Sharmila Shankar; Rakesh K Srivastava
Journal:  Biochem Pharmacol       Date:  2011-07-30       Impact factor: 5.858

Review 2.  Protein lysine acetylation by p300/CBP.

Authors:  Beverley M Dancy; Philip A Cole
Journal:  Chem Rev       Date:  2015-01-16       Impact factor: 60.622

3.  Molecular mechanisms of green tea polyphenols.

Authors:  Q Ping Dou
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

Review 4.  Cancer preventive mechanisms of the green tea polyphenol (-)-epigallocatechin-3-gallate.

Authors:  Lei Chen; Hong-Yu Zhang
Journal:  Molecules       Date:  2007-05-03       Impact factor: 4.411

5.  Discovery of DNA Topoisomerase I Inhibitors with Low-Cytotoxicity Based on Virtual Screening from Natural Products.

Authors:  Lan-Ting Xin; Lu Liu; Chang-Lun Shao; Ri-Lei Yu; Fang-Ling Chen; Shi-Jun Yue; Mei Wang; Zhong-Long Guo; Ya-Chu Fan; Hua-Shi Guan; Chang-Yun Wang
Journal:  Mar Drugs       Date:  2017-07-09       Impact factor: 5.118

Review 6.  Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases.

Authors:  Chetan Kumar Jain; Hemanta Kumar Majumder; Susanta Roychoudhury
Journal:  Curr Genomics       Date:  2017-02       Impact factor: 2.236

7.  Polyphenol Polymerization by an Alternative Oxidative Microbial Enzyme and Characterization of the Biological Activity of Oligomers.

Authors:  Patrizia Di Gennaro; Valentina Sabatini; Silvia Fallarini; Roberto Pagliarin; Guido Sello
Journal:  Biomed Res Int       Date:  2018-04-23       Impact factor: 3.411

8.  Flavonoids uptake and their effect on cell cycle of human colon adenocarcinoma cells (Caco2).

Authors:  M Salucci; L A Stivala; G Maiani; R Bugianesi; V Vannini
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

9.  Progress in nanotechnology based approaches to enhance the potential of chemopreventive agents.

Authors:  Irfana Muqbil; Ashiq Masood; Fazlul H Sarkar; Ramzi M Mohammad; Asfar S Azmi
Journal:  Cancers (Basel)       Date:  2011-01-21       Impact factor: 6.639

Review 10.  An Association Map on the Effect of Flavonoids on the Signaling Pathways in Colorectal Cancer.

Authors:  Sanaz Koosha; Mohammed A Alshawsh; Chung Yeng Looi; Atefehalsadat Seyedan; Zahurin Mohamed
Journal:  Int J Med Sci       Date:  2016-04-29       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.